TargetGene is an Israeli SME. We are a recognized innovative pioneer in the gene-editing field with our proprietary, best-in-class T-GEE platform. T-GEE is a super-precise dual-guide-based system as versatile as CRISPR but without the latter's off-target safety concerns. Today, we leverage T-GEE's advantages to rewire cell transcriptomes to develop safe and effective cell therapies for cancer, immune-related diseases, and genetic disorders.